These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30109144)

  • 81. Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.
    Zhang C; Ma K; Li WY
    Drug Des Devel Ther; 2019; 13():4075-4090. PubMed ID: 31824138
    [TBL] [Abstract][Full Text] [Related]  

  • 82. TCDD-mediated suppression of naïve human B cell IgM secretion involves aryl hydrocarbon receptor-mediated reduction in STAT3 serine 727 phosphorylation and is restored by interferon-γ.
    Blevins LK; Zhou J; Crawford R; Kaminski NE
    Cell Signal; 2020 Jan; 65():109447. PubMed ID: 31678681
    [TBL] [Abstract][Full Text] [Related]  

  • 83. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Neoplasia; 2015 Sep; 17(9):687-696. PubMed ID: 26476076
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells.
    Chung SY; Chen YH; Lin PR; Chao TC; Su JC; Shiau CW; Su Y
    Cell Death Discov; 2018; 4():25. PubMed ID: 30109144
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM; Grothey A
    Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Second-line systemic therapy for metastatic colorectal cancer.
    Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
    Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
    Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways.
    Sharma Y; Ahmad A; Bashir S; Elahi A; Khan F
    Future Oncol; 2016 May; 12(10):1287-98. PubMed ID: 26987952
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.
    Zhao C; Wang W; Yu W; Jou D; Wang Y; Ma H; Xiao H; Qin H; Zhang C; Lü J; Li S; Li C; Lin J; Lin L
    Oncotarget; 2016 Mar; 7(11):12917-26. PubMed ID: 26883202
    [TBL] [Abstract][Full Text] [Related]  

  • 92. IGF/STAT3/NANOG/Slug Signaling Axis Simultaneously Controls Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer.
    Yao C; Su L; Shan J; Zhu C; Liu L; Liu C; Xu Y; Yang Z; Bian X; Shao J; Li J; Lai M; Shen J; Qian C
    Stem Cells; 2016 Apr; 34(4):820-31. PubMed ID: 26840943
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cancer statistics, 2016.
    Siegel RL; Miller KD; Jemal A
    CA Cancer J Clin; 2016; 66(1):7-30. PubMed ID: 26742998
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer.
    Yuan J; Zhang F; Niu R
    Sci Rep; 2015 Dec; 5():17663. PubMed ID: 26631279
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation.
    Moreno CC; Mittal PK; Sullivan PS; Rutherford R; Staley CA; Cardona K; Hawk NN; Dixon WT; Kitajima HD; Kang J; Small WC; Oshinski J; Votaw JR
    Clin Colorectal Cancer; 2016 Mar; 15(1):67-73. PubMed ID: 26602596
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism.
    Zhao C; Li H; Lin HJ; Yang S; Lin J; Liang G
    Trends Pharmacol Sci; 2016 Jan; 37(1):47-61. PubMed ID: 26576830
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Therapies targeting cancer stem cells: Current trends and future challenges.
    Dragu DL; Necula LG; Bleotu C; Diaconu CC; Chivu-Economescu M
    World J Stem Cells; 2015 Oct; 7(9):1185-201. PubMed ID: 26516409
    [TBL] [Abstract][Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.